Vail Scientific was founded with the mission to save lives through the early detection of sepsis. The company envisions a world where patients can be quickly and accurately screened for sepsis at the point of care, reducing healthcare risks and costs associated with this life-threatening condition. Vail Scientific develops medical devices that analyze exhaled breath to measure nitric oxide and carbon dioxide levels. Their proprietary algorithm predicts the probability of sepsis risk, enabling rapid diagnosis and timely treatment.

Notable affiliated individuals and investors include experts in medical technology and healthcare innovation, although specific names are not disclosed. Key achievements include the development of a patent-pending early-detection screening technology that has the potential to revolutionize sepsis diagnosis. Vail Scientific's impact lies in its innovative approach to non-invasive diagnostics, which could significantly improve patient outcomes and reduce the burden on healthcare systems worldwide.